Corticosteroid tied to shorter recovery in non-severe COVID-19Inhaled budesonide, a corticosteroid often used for Crohn's disease, was tied to a shorter recovery time in COVID-19 patients who were at a higher risk of severe infection, according to a study published in The Lancet yesterday.The researchers used UK residents 65 or older or who were 50 and older with comorbidities who were enrolled in the larger PRINCIPLE trial.
Patients were unwell with suspected COVID-19 for up to 14 days (median, 6 days), and were randomized to budesonide from Nov 27, 2020, to Mar 31, 2021.
In the primary analysis group, 787 received budesonide and usual care, 1,069 received usual care, and 974 were part of other treatment groups.